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Abstract
AIM
To evaluate the efficacy of antimicrobial susceptibility-guided therapy before first-line treatment for
infection in patients with dual or triple antibiotic resistance.
METHODS
A total of 1034 patients infected by Helicobacter pylori (H. pylori) during 2013-2014 were tested for
antimicrobial susceptibility. 157 of 1034 (15%) patients showed resistance to two (127/1034; 12%)
and to three (30/1034; 3%) antibiotics. Sixty-eight patients with dual H. pylori-resistance
(clarithromycin, metronidazole or levofloxacin) were treated for 10 d with triple therapies: OAL
(omeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., and levofloxacin 500 mg b.i.d.) 43 cases, OAM
(omeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., and metronidazole 500 mg b.i.d.) 12 cases and OAC
(omeprazole 20 mg b.id., amoxicillin 1 g b.i.d., and clarithromycin 500 mg b.i.d.) 13 cases based on
the antimicrobial susceptibility testing. Twelve patients showed triple H. pylori-resistance
(clarithromycin, metronidazole and levofloxacin) and received for 10 d triple therapy with OAR
(omeprazole 20 mg b.id., amoxicillin 1 g b.i.d., and rifabutin 150 mg b.i.d.). Eradication was confirmed
by 13C-urea breath test. Adverse effects and compliance were assessed by a questionnaire.
RESULTS
Intention-to-treat eradication rates were: OAL (97.6%), OAM (91.6%), OAC (92.3%) and OAR
(58.3%). Cure rate was significantly higher in naïve patients treated with OAR-10 compared to patients
who had two or three previous treatment failures (83% vs 33%). Adverse events rates for OAL, OAM,
OAC and OAR were 22%, 25%, 23% and 17%, respectively, all of them mild-moderate.
CONCLUSION
Antimicrobial susceptibility-guided triple therapies during 10 d for first-line treatment leads to an
eradication rate superior to 90% in patients with dual antibiotic H. pylori resistance.
Key Words: Helicobacter pylori (https://www.f6publishing.com/ArticlesByKeywords?type=2&
pageNumber=1&keyword=%3citalic%3eHelicobacter+pylori%3c%2fitalic%3e), Resistance
(https://www.f6publishing.com/ArticlesByKeywords?type=2&pageNumber=1&keyword=Resistance),
Eradication rate (https://www.f6publishing.com/ArticlesByKeywords?type=2&pageNumber=1&
keyword=Eradication+rate), Antimicrobial susceptibility (https://www.f6publishing.com
/ArticlesByKeywords?type=2&pageNumber=1&keyword=Antimicrobial+susceptibility), Therapies
(https://www.f6publishing.com/ArticlesByKeywords?type=2&pageNumber=1&keyword=Therapies)
Core tip: This study evaluated the efficacy of antimicrobial susceptibility-guided therapy: proton-pump
inhibitor and two or three antibiotics for ten days before first-line treatment in patients with dual or
triple Helicobacter pylori resistance to clarithromycin, metronidazole and/or levofloxacin. Intention to
treat analysis demonstrates that eradication rates in patients with dual Helicobacter pylori resistance
are high (around 95%). Cure rate was significantly higher in naive patients with dual resistance
compared to those with triple resistance (95% vs 83%).
Citation: Cosme A, Montes M, Ibarra B, Tamayo E, Alonso H, Mendarte U, Lizasoan J, Herreros-
Villanueva M, Bujanda L. Antimicrobial susceptibility testing before first-line treatment for Helicobacter
pylori infection in patients with dual or triple antibiotic resistance. World J Gastroenterol 2017; 23(18):
3367-3373
INTRODUCTION
Helicobacter pylori (H. pylori) eradication therapy success is compromised mainly due to antibiotic
resistance. Resistance prevalence varies by country and within same region by periods of time. Among
possible causes of failure are the increased use of different antibiotics in the general population- adult
and children for dental, respiratory, gynecological and parasitic infectious diseases.
Prevalence of H. pylori antibiotic resistance has been increasing remarkably worldwide and
concordantly, eradication rate has been declining globally[1]. Since multiresistance is frequently
developed against most commonly implemented antibiotics and this phenomena leads to an increasing
inadequate success rates, new therapeutic strategies are urgently needed.
In Gipuzkoa, a region in Northern Spain, during 2006-2012 the prevalence of clarithromycin-resistant
H. pylori varied from 15.7% to 21.6% and from 32% to 44.3% for metronidazole. Between 2000 and
2012, the resistance to two or three antibiotics (clarithromycin, metronidazole, or/and levofloxacin)
was observed in 14.8% of 5998 H. pylori isolates tested for antimicrobial susceptibility[2].
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The objective of our study was to evaluate the efficacy of antimicrobial susceptibility-guided therapy:
proton-pump inhibitor (PPI) and two antibiotics for ten days before first-line treatment in patients with
dual H. pylori-resistance (clarithromycin, metronidazole or levofloxacin) or triple H. pylori-resistance
(clarithromycin, metronidazole and levofloxacin).
MATERIALS AND METHODS
Patients and study protocol
This was a prospective observational study including all patients infected by H. pylori during 2013 and
2014 in our region. Susceptibility testing was performed in all strains isolates from gastric biopsies.
Exclusion criteria included severe concomitant disease (insulin-dependent type I diabetes mellitus and
neoplastic diseases), previous gastric surgery, pregnancy or lactation, and allergy to any of the drugs
used in the study.
This study was conducted in accordance with the principles of the Declaration of Helsinki, ICH
Guidelines for Good Clinical Practice and full conformity with relevant regulations.
Culture and microbial susceptibility testing
For each patient, two antral and two corpus biopsies were taken for the bacterial culture. Susceptibility
testing was assessed by E-test (BioMerieux) in 1034 patients. Primary and relapse isolates were
included. E-test strips were placed on Brucella agar plates with 5% hemolized horse blood,
supplemented with 1% Vitox and were incubated at 37 °C for 48-72 h under microaerophilic conditions
with 80% humidity[3].
It was observed that 53.3% (551/1034) of isolates were resistant to at least one antibiotic, 12.3% of
them to two antibiotics and 2.9% to three antibiotics (Figure 1). In Gipuzkoa the rate of H. pylori
amoxicillin resistance was 0%. It is well known that resistance to clarithromycin and fluoroquinolone
are mainly codified in the 23SrRNA and gyrA genes, respectively.
(http://www.wjgnet.com/1007-9327/full/v23/i18/WJG-23-3367-g001.htm)
Figure 1 Relation of simultaneous antibiotic resistance of Helicobacter pylori to various
antibiotics in Gipuzkoa 2013/2014 (n = 1034).
Therapeutic regimen
Patients with dual H. pylori-resistance were treated based on the antimicrobial susceptibility results:
(1) levofloxacin-based triple therapy: omeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., and levofloxacin
500 mg b.i.d. (OAL), if the H. pylori-isolates were resistant to clarithromycin and metronidazole but
sensitive to levofloxacin; (2) metronidazole-based triple therapy: omeprazole 20 mg b.i.d., amoxicillin
1 g b.i.d., and metronidazole 500 mg b.i.d. (OAM), if the H. pylori-isolates were resistant to both
clarithromycin and levofloxacin but sensitive to metronidazole; and (3) clarithromycin-based triple
therapy: omeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., and clarithromycin 500 mg b.i.d. (OAC), if the
H. pylori-isolates were resistant to metronidazole and levofloxacin but sensitive to clarithromycin, in all
cases twice a day for 10 d.
Patients with triple H. pylori-resistance to clarithromycin, metronidazole and levofloxacin received
rifabutin-based triple therapy: omeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., and rifabutin 150 mg
b.i.d. (OAR) for 10 d. No patients had previously received rifampicin and 6 of them referred two or
three H. pylori eradication failures (3 with OAC and bismuth quadruple therapy, 2 with OAC, bismuth
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quadruple therapy and OAL, and 1 with OAC and OAL, in all cases for 10 d).
Treatment was clearly explained to all patients. Drugs were self-administered orally after meals. Drugs
used in all groups were generic branding.
Trial outcomes
Primary end point: confirmed H. pylori eradication by intention-to-treat (ITT) in each group of at least 6
wk after treatment completion using the urea breath test (UBT) with 100 mg of urea, in accordance
with a previously described protocol[3].
Secondary end point: adherence to treatment regimen and adverse events associated with treatment.
Adherence to treatment was defined as in take of -at least- 90% of the medication prescribed assessed
by using a questionnaire and counting empty medication sachets returned. Side effects were evaluated
with a specific postreatment questionnaire completed. Depending of the intensity, adverse effects were
classified by physicians as mild (symptoms appear but do not interfere with daily life), moderate
(symptoms interfere with daily life) or severe (symptoms prevent daily life or requires discontinuation
of the drug).
RESULTS
A total of 1034 H. pylori-positive consecutive adult patients with antimicrobial-susceptibility testing
were enrolled from January 2013 to December 2014 in Gipuzkoa (Basque Country), a region in
Northern Spain of around 700000 residents. Considering the total of patients, dual H. pylori-resistance
to two antimicrobials (clarithromycin, metronidazole or levofloxacin) was observed in 127 (12.3%) and
triple H. pylori-resistance to three antimicrobials in 30 (2.9%) of them. Patients with dual H. pylori-
resistance were treated with OAL-10, OAM-10 or OAC-10 d, and patients with triple H. pylori-resistance
with OAR-10 d. A subgroup of 80 patients (68 with dual H. pylori-resistance, and 12 with triple H.
pylori-resistance) attending to Donostia Hospital (San Sebastián, Spain) were only included. The
population represented in this area of San Sebastián is around 393000 residents (Figure 2).
 (http://www.wjgnet.com
/1007-9327/full/v23/i18/WJG-23-3367-g002.htm)
Figure 2 Flow diagram of screening and follow-up of study subjects. Susceptibility testing for
H. pylori resistance was performed in 1034 consecutive infected patients. A total of 157 patients
showed dual (127, 12.3%) or triple (30, 2.9%) antibiotic resistance. Patients from Donosti area were
selected for follow up (68 with dual and 12 with triple resistance). 43 patients resistant to
clarithromycin and metronidazole but sensitive to levofloxacin were treated with levofloxacin-based
triple therapy: omeprazole 20 mg, amoxicillin 1 g, and levofloxacin 500 mg (OAL); 12 patients
resistant to both clarithromycin and levofloxacin were treated with metronidazole-based triple
therapy: omeprazole 20 mg, amoxicillin 1 g, and metronidazole 500 mg (OAM); 13 resistant patients
to metronidazole and levofloxacin were treated with clarithromycin-based triple therapy: omeprazole
20 mg amoxicillin 1 g, and clarithromycin 500 mg (OAC), if the H. pylori-strains werein all cases twice
a day for 10 d. 12 patients with triple H. pylori-resistance to clarithromycin, metronidazole and
levofloxacin received rifabutin-based triple therapy: omeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d.,
and rifabutin 150 mg b.i.d. (OAR) for 10 d.
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Baseline characteristics of each group of patients, efficacy of therapy on H. pylori-eradication,
compliance and adverse events are shown in Table 1. ITT analysis demonstrated that eradication rates
in patients with dual H. pylori-resistance treated with OAL-10, OAM-10, and OAC-10 were 97.6%
(42/43), 91.6% (11/12) and 92.3% (12/13), respectively, and with triple H. pylori-resistance treated
with OAR-10, 58.3% (7/12). The eradication rate in naïve patients with OAR-10 was 83% (5/6) and
33% (2/6) in patients after previous regimen failures (OAC and bismuth quadruple therapy, and OAC,
bismuth quadruple therapy and OAL, respectively).
Table 1  (http://www.wjgnet.com/1007-9327/full/v23/i18/3367-T1.htm) Demographic, clinical characteristics,
eradication rates per intention-to-treat, compliance and adverse events of patients in each therapeutics group.
Dual H. pylori - resistance Triple H. pylori- resistance
C + M C + L M + L C + M + L
OAL-10 OAM-10 OAC-10 OAR-10
(43) (12) (13) (12)
Gender (females) 70% 67% 69% 67%
Age (yr)
Mean 51.6 52.8 50 53.3
Median (range) 51 (18-76) 52 (24-76) 50 (31-75) 53 (42-77)
Indication
Dyspepsia 95% 83% 84% 75%
Ulcer 5% 17% 16% 25%
ITT eradication 42/43 (97.6%) 11/12 (91.6%) 12/13 (92.3%) 7/12 (58.3%)
Compliance 93% 93% 93% 94%
Adverse events 22% 25% 23% 17%
O: Omeprazole; A: Amoxicillin; L: Levofloxacin; M: Metronidazole; C: Clarithromycin; R: Rifabutin; H. pylori:
Helicobacter pylori; ITT: Intention-to-treat.
Seventy-five out of 80 patients with dual or triple H. pylori-resistance showed 100% compliance to
prescribed medications. No significant differences were observed in compliance between patients with
dual and triple H. pylori-resistance (93% vs 94% respectively).
Adverse events rate for OAL, OAM, OAC, and OAR were 22% (abdominal pain in 3 patients, nausea in 3
patients, asthenia in 1 patient, diarrhea in 1 patient and metallic taste in 1 patient), 25% (myalgia in 1
patient and metallic taste in 2 patients), 23% (diarrhea in 1 patient, nausea in 1 patient and metallic
taste in 1 patient) and 17% (headache in 1 patient, and increased transaminases in 1 patient)
respectively, all of them classified as mild to moderate.
DISCUSSION
In this study we demonstrated that in patients with dual clarithromycin, levofloxacin or metronidazole
resistance, antimicrobial susceptibility-guided therapy including a combination of PPI and two
antibiotics for 10 d leads to an eradication rate (evaluated by ITT) of 95.5%.
In our reference center-Donostia Hospital, cultures are carried out as “routine practice” since 1994[4].
During 1994-1998 dual H. pylori-resistance to two antimicrobials (clarithromycin, metronidazole or
levofloxacin) was 10.5%[4,5]. In Gipuzkoa (Basque country), from 2000-2012 the dual resistance was
observed in 12.4% of isolates of H. pylori[2], being 12.3% considering the period 2013-2014. By
contrast, multiple H. pylori-resistance to three antimicrobials increased from 2.4% during the period
2000-2012 to 2.9% for the period 2013-2014.
Patients with dual or triple resistance represents a new scenario to evaluate efficacy of current
antibiotics regimens. According to the Maastrich V/Florence Consensus Conference on managing H.
pylori, bismuth quadruple therapy (BQT) for first-line treatment or non-bismuth quadruple concomitant
therapy (non-BQT) as alternative were recommended when clarithromycin resistance of H. pylori is >
15%, metronidazole H. pylori-resistance is less than 40% and dual clarithromycin and metronidazole H.
pylori-resistance is < 15%[6].
In patients with dual clarithromycin and metronidazole H. pylori resistance, Georgopoulos et al[7],
reported 78% (18 out 23) of eradication rates when non-bismuth quadruple concomitant therapy (PPI
regime plus amoxicillin, clarithromycin and metronidazole for 10 d) was prescribed and 33% (9 out 27)
with quadruple sequential therapy administration (5 d PPI plus amoxicillin, followed by a further 5 d
with clarithromycin and metronidazole). Recently, in the European H. pylory Registry (31 countries and
18270 pacients with complete treatment, 12% of them with culture and antibiogram), eradication rates
with quadruple concomitant and sequential therapy were 80% (4 of 5) and 62.5% (5 of 8)
respectively[8].
On the other hand, the eradication rate with bismuth quadruple therapy for 10 d was lower in
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pretreated patients with metronidazole resistance[9,10]. Furthermore, different studies analyzing
bismuth quadruple therapy concluded that in vitro resistant strains to metronidazole could be
effectively heated by using higher doses of metronidazole administrated for 14 d[11,12]. However, this
classic bismuth quadruple therapy requires a complex scheme of administration, increases side effects
and it is not worldwide available due to distribution restrictions.
A number of strategies have been recommended to potentially overcome dual H. pylori-resistance
(clarithromycin and metronidazole) including longer duration of quadruple therapies (concomitant-14 d,
bismuth -14 d), higher dose of new-generations - PPIs (esomeprazole or rabeprazole), hybrid therapy
(a 7 d of PPI plus amoxicillin, followed by 7 d of PPI, amoxicillin, clarithromycin and metronidazole) or
quadruple therapy with levofloxacin and bismuth - 14 d (PPI regime plus amoxicillin, bismuth and
levofloxacin)[13-16]. Quadruple sequential therapy (14 d), hybrid therapy and non-bismuth quadruple
concomitant therapy (14 d) are expected to fail if the rate of dual clarithromycin and metronidazole
resistant strains are > 5%, > 9%, and > 15%, respectively[7]. Our results showed that antimicrobial
susceptibility-guided triple therapies for 10 d in a population with clarithromycin - H. pylori resistance >
16% and dual H. pylori-resistance (clarithromycin, metronidazole or levofloxacin) > 12% was more
effective than quadruple therapies for first-line (BQT or non-BQT) for first-line treatment.
In this study eradication rate of OAR for 10 d in naïve patients with triple H. pylori-resistance
(clarithromycin, metronidazole and levofloxacin) was 83% (5 of 6) vs 33% (2 of 6) in patients after two
or three previous H. pylori treatment failures. Several studies have confirmed that most of rifabutin-
resistant isolates of H. pylori were obtained from patients after treatment failures, suggesting that
previous unsuccessful attempts of eradication seem to be an important risk factor for the development
of resistance to rifabutin and/or multiple resistance[17,18]. Rifabutin rescue regimen is effective after
multiple previous H. pylori eradication failures[19,20]. A recent study, involving nine Spanish hospitals
and 100 consecutive patients, supports that the use of rifabutin-based rescue therapy in patients with
three H. pylori eradication failures (OAC, BQT, and OAL, in all cases for 10 d) may be effective in
approximately 50% of the cases[21].
Different virulence factors play an important role in the pathogenesis of H. pylori and treatment
resistance. For instance, a significant association has been found between dupA1 genotype and A214G
clarithromycin resistance mutation by Hussein et al[22]. Further molecular studies are needed in order
to clarify biomarkers that could causes of H. pylori resistance.
Some of the limitations of this study were: first, the number of patients is too limited to draw definitive
conclusions on the efficacy of these therapies. Second, rifabutin resistance evaluation was not assessed
in patients treated with rifabutin-based triple therapy either before or after administration.
Dual or triple H. pylori-resistance to various families of antimicrobials may be addressed by the
adequate use of antibiotics, in a cost-effective manner and shortening the regimens as much as
possible.
In summary, triple therapies including PPI and two antibiotics for 10 d, based in the knowledge of
pretreatment antimicrobial susceptibility showed good eradication rates of H. pylori infection in our
region with an increased prevalence of dual or triple drugs H. pylori-resistance (clarithromycin,
metronidazole and/or levofloxacin).
COMMENTS
Background
Frequency of dual or triple antimicrobial resistance has been rising during the last decade and
Helicobacter pylori (H. pylori) infections are an important challenge for physicians. To tailor
recommendations for optimal treatments, efficacy evaluations must be performed in different
geographical areas.
Research frontiers
H. pylori eradication therapy success is compromised mainly due to antibiotic resistance and numerous
researchers are trying to overcome multiresistance. Resistance prevalence varies by country and within
same region, by periods of time. The aim of this study was to evaluate the efficacy of antimicrobial
susceptibility-guided therapy before first-line treatment for infection in patients with dual or triple
antibiotic resistance.
Innovations and breakthroughs
In this study the authors demonstrated that in patients with dual clarithromycin, levofloxacin or
metronidazole resistance, antimicrobial susceptibility-guided therapy including a combination of PPI and
two antibiotics for 10 d leads to an eradication rate of 95.5%. Compared to different strategies
previously purposed, our results shows that antimicrobial susceptibility-guided triple therapies for 10 d
in a population with clarithromycin - H. pylori resistance > 16% and dual H. pylori-resistance
(clarithromycin, metronidazole or levofloxacin) > 12% was more effective than quadruple therapies for
first-line treatment of infections.
Applications
Dual or triple H. pylori resistance to various families of antimicrobials may be addressed by the
adequate use of antibiotics in a cost-effective manner that allows shorter regimens.
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Terminology
Common therapies for H. pylori treatment. Triple therapies: OAL (omeprazole 20 mg b.id., amoxicillin 1
g b.i.d., and levofloxacin 500 mg b.i.d.) 43 cases, OAM (omeprazole 20 mg b.id., amoxicillin 1 g b.i.d.,
and metronidazole 500 mg b.i.d.) 12 cases and OAC (omeprazole 20 mg b.id., amoxicillin 1 g b.i.d.,
and clarithromycin 500 mg b.i.d.) 13 cases based on the antimicrobial susceptibility testing. Twelve
patients showed triple H. pylori-resistance and received for 10 d triple therapy with OAR (omeprazole
20 mg b.id., amoxicillin 1 g b.i.d., and rifabutin 150 mg b.i.d.).
Peer-review
In the present paper, Cosme et al evaluated the impact of antimicrobial resistance in H. pylori in the
first line eradication therapy. Starting from a sample size of 1034 patients undergoing culture, they
selected cases with double or triple resistance and assigned a tailored triple therapy (omeprazole +
amoxicillin + clarithromycin or metronidazole or levofloxacin or rifabutin). Therefore, they
demonstrated a success rate > 90% in all regimens, excluding when rifabutin was adopted (58.3%) in
triple resistant strains.
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